{"id":"rifaximin-xifaxan","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Flatulence"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1617","moleculeType":"Small molecule","molecularWeight":"785.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifaximin is a rifamycin-class antibiotic that acts locally in the gastrointestinal tract by inhibiting bacterial RNA polymerase, thereby suppressing the growth of gram-positive and gram-negative enteric bacteria. Because it is minimally absorbed from the GI tract, it achieves high local concentrations in the gut while maintaining low systemic exposure, making it suitable for treating local GI infections and conditions driven by dysbiosis.","oneSentence":"Rifaximin is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria without systemic absorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:02.459Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Traveler's diarrhea caused by noninvasive strains of Escherichia coli"},{"name":"Hepatic encephalopathy (reduction of overt episodes)"},{"name":"Irritable bowel syndrome with diarrhea (IBS-D)"}]},"trialDetails":[{"nctId":"NCT07285785","phase":"PHASE4","title":"Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea","status":"RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2026-02-11","conditions":"Diarrhea, Gastroenteritis, Bacterial Infection","enrollment":54},{"nctId":"NCT05159427","phase":"PHASE1","title":"Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2022-03-15","conditions":"Human Gastrointestinal Physiology Data","enrollment":40},{"nctId":"NCT07454408","phase":"PHASE1, PHASE2","title":"Evaluation of the Outcome of Fecal Microbiota Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2026-03-07","conditions":"Hepatic Encephalopathy, Fecal Microbiota Transplantation, TIPS","enrollment":40},{"nctId":"NCT07429760","phase":"NA","title":"Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2025-08-01","conditions":"Colorectal Cancer","enrollment":60},{"nctId":"NCT07426705","phase":"PHASE4","title":"Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","startDate":"2026-02-15","conditions":"Small Intestinal Bacterial Overgrowth Syndrome (SIBO), IBS","enrollment":100},{"nctId":"NCT07422948","phase":"NA","title":"Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-05","conditions":"Acute on Chronic Liver Failure","enrollment":113},{"nctId":"NCT07381257","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Rifaximin-α in Treating MASLD","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-01-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease","enrollment":60},{"nctId":"NCT07209371","phase":"PHASE2","title":"Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-01-22","conditions":"IgA Monoclonal Gammopathy of Undetermined Significance","enrollment":50},{"nctId":"NCT03729271","phase":"PHASE4","title":"Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2020-01-09","conditions":"Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea","enrollment":148},{"nctId":"NCT04244877","phase":"PHASE3","title":"Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility","status":"WITHDRAWN","sponsor":"MetroHealth Medical Center","startDate":"2021-09-15","conditions":"Cirrhosis, Liver, Minimal Hepatic Encephalopathy, Small Intestinal Bacterial Overgrowth","enrollment":""},{"nctId":"NCT05253287","phase":"PHASE2, PHASE3","title":"Growth Hormone in Decompensated Liver Cirrhosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-02-01","conditions":"Liver Cirrhosis, Fibrosis, End Stage Liver Disease","enrollment":96},{"nctId":"NCT06223685","phase":"NA","title":"The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin","status":"COMPLETED","sponsor":"Pomeranian Medical University Szczecin","startDate":"2023-04-01","conditions":"Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth, SIBO","enrollment":129},{"nctId":"NCT06727422","phase":"PHASE2","title":"Efficacy of Rifaximin With NAC in IBS-D","status":"NOT_YET_RECRUITING","sponsor":"Mark Pimentel, MD","startDate":"2025-12-15","conditions":"IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)","enrollment":225},{"nctId":"NCT04254549","phase":"PHASE2","title":"Rifaximin in Patients With Diabetic Gastroparesis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2019-06-14","conditions":"Crohn Disease, Diabetic Gastroparesis","enrollment":5},{"nctId":"NCT07203846","phase":"PHASE4","title":"Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor","status":"NOT_YET_RECRUITING","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2026-01-01","conditions":"ACS - Acute Coronary Syndrome, Ticagrelor, Microbiota","enrollment":50},{"nctId":"NCT07185932","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Rifaximin in Treating MAFLD","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-08-10","conditions":"Metabolic-associated Fatty Liver Disease","enrollment":40},{"nctId":"NCT06443502","phase":"PHASE3","title":"A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-19","conditions":"Pouchitis","enrollment":30},{"nctId":"NCT07180615","phase":"PHASE4","title":"Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery","status":"NOT_YET_RECRUITING","sponsor":"Universität Luzern","startDate":"2026-06-01","conditions":"Surgical Site Infection, Colon Surgery, Surgical Site Infections","enrollment":458},{"nctId":"NCT04249622","phase":"PHASE2","title":"Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2020-09-18","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":20},{"nctId":"NCT05297448","phase":"PHASE3","title":"Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-08-03","conditions":"Hepatic Encephalopathy","enrollment":466},{"nctId":"NCT03575195","phase":"PHASE1, PHASE2","title":"Microbiota Intervention to Change the Response of Parkinson's Disease","status":"SUSPENDED","sponsor":"University of California, San Francisco","startDate":"2019-07-15","conditions":"Parkinson Disease","enrollment":86},{"nctId":"NCT05754996","phase":"PHASE3","title":"Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-03-12","conditions":"Hepatic Encephalopathy","enrollment":80},{"nctId":"NCT06483737","phase":"NA","title":"Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":"Overt Hepatic Encephalopathy","enrollment":174},{"nctId":"NCT06058572","phase":"PHASE2","title":"Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-08-02","conditions":"Acute Leukemia","enrollment":166},{"nctId":"NCT05071716","phase":"PHASE3","title":"Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-04-07","conditions":"Hepatic Encephalopathy","enrollment":524},{"nctId":"NCT05453916","phase":"PHASE1, PHASE2","title":"Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2022-07-01","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":""},{"nctId":"NCT06312683","phase":"PHASE4","title":"Rifaximin for the Secondary Prevention of Recurrent Pouchitis","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-07-01","conditions":"Pouchitis","enrollment":16},{"nctId":"NCT05408910","phase":"PHASE2, PHASE3","title":"Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2025-07","conditions":"Cystic Fibrosis, Abdominal Pain, Small Bowel Disease","enrollment":""},{"nctId":"NCT07037394","phase":"PHASE4","title":"A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.","status":"COMPLETED","sponsor":"Qurratul Ain Jamil","startDate":"2024-12-02","conditions":"Overt Hepatic Encephalopathy","enrollment":252},{"nctId":"NCT06298409","phase":"PHASE1","title":"Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®","status":"RECRUITING","sponsor":"Envivo Bio Inc","startDate":"2024-02-15","conditions":"Small Intestinal Bacterial Overgrowth","enrollment":34},{"nctId":"NCT06538077","phase":"PHASE4","title":"BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-02-01","conditions":"Hepatic Encephalopathy, Decompensated Cirrhosis, Minimal Hepatic Encephalopathy","enrollment":336},{"nctId":"NCT05677282","phase":"PHASE4","title":"Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2022-10-28","conditions":"Diarrhoea;Acute, Diarrhea Travelers","enrollment":150},{"nctId":"NCT06852274","phase":"NA","title":"Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study","status":"COMPLETED","sponsor":"Dr. Amjad Khan","startDate":"2023-03-01","conditions":"Diverticular Diseases, Gastro-Intestinal Disorder","enrollment":70},{"nctId":"NCT06772064","phase":"NA","title":"Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.","status":"RECRUITING","sponsor":"Xiuli Zuo","startDate":"2025-04-15","conditions":"SIBO","enrollment":115},{"nctId":"NCT03219528","phase":"PHASE4","title":"A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2018-02-13","conditions":"Irritable Bowel Syndrome","enrollment":74},{"nctId":"NCT05204641","phase":"PHASE2","title":"Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2022-01-04","conditions":"Parkinson Disease","enrollment":59},{"nctId":"NCT03820817","phase":"PHASE1","title":"Rifaximin in Patients With Monoclonal Gammopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-05-15","conditions":"IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy, IgM Monoclonal Gammopathy","enrollment":50},{"nctId":"NCT03069131","phase":"PHASE3","title":"Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2018-06-05","conditions":"Cirrhosis, Ascites, Peritonitis","enrollment":160},{"nctId":"NCT06743464","phase":"NA","title":"Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-12-01","conditions":"Chronic Liver Disease","enrollment":100},{"nctId":"NCT05604274","phase":"","title":"Longitudinal Monitoring of Stool Characteristics","status":"COMPLETED","sponsor":"Hunter Holmes Mcguire Veteran Affairs Medical Center","startDate":"2022-10-28","conditions":"Cirrhosis, Liver","enrollment":60},{"nctId":"NCT06808009","phase":"NA","title":"Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-05","conditions":"Acute on Chronic Liver Failure","enrollment":90},{"nctId":"NCT04073290","phase":"PHASE4","title":"Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2020-01-21","conditions":"Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension","enrollment":238},{"nctId":"NCT06783153","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-01-20","conditions":"Radiotherapy Induced Diarrhea, Acute Radiation Enteritis, Prostate Cancer","enrollment":80},{"nctId":"NCT06718686","phase":"PHASE1, PHASE2","title":"Rifaximin SSD in Dementia Trial","status":"RECRUITING","sponsor":"Jasmohan Bajaj","startDate":"2024-12-30","conditions":"Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease","enrollment":20},{"nctId":"NCT05587036","phase":"PHASE2, PHASE3","title":"Effects of Rifaximin on Gut Microbiota and Emotion","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-02-02","conditions":"Healthy Volunteers, Stress, Fear","enrollment":60},{"nctId":"NCT06652087","phase":"NA","title":"Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction","status":"RECRUITING","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2024-09-02","conditions":"Bacterial Overgrowth Syndrome Small Bowel, Heart Failure with Preserved Ejection Fraction","enrollment":40},{"nctId":"NCT06630572","phase":"PHASE4","title":"Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes","status":"TERMINATED","sponsor":"University of Roma La Sapienza","startDate":"2021-04-03","conditions":"Liver Cirrhosis, Coagulation Disorder, Platelet Disorder","enrollment":20},{"nctId":"NCT02193763","phase":"NA","title":"Bedside Ultrasound Assisted Pediatric Lumbar Puncture","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2009-08","conditions":"Infant/ Neonate Lumbar Puncture","enrollment":""},{"nctId":"NCT05098028","phase":"PHASE2","title":"Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-03-22","conditions":"Sickle Cell Disease","enrollment":44},{"nctId":"NCT06518850","phase":"PHASE1, PHASE2","title":"Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-08-01","conditions":"Small Intestine Bacterial Overgrowth","enrollment":30},{"nctId":"NCT01345175","phase":"PHASE3","title":"Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-04-26","conditions":"Rectal Cancer","enrollment":69},{"nctId":"NCT04199910","phase":"","title":"4beta-hydroxycholesterol in Cirrhosis","status":"SUSPENDED","sponsor":"University of Oulu","startDate":"2019-12-01","conditions":"Cirrhosis, Liver","enrollment":120},{"nctId":"NCT05150587","phase":"PHASE2","title":"Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea","status":"COMPLETED","sponsor":"Alfasigma S.p.A.","startDate":"2021-10-05","conditions":"Papulopustular Rosacea","enrollment":216},{"nctId":"NCT06368895","phase":"PHASE1","title":"Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-04-07","conditions":"Hepatic Encephalopathy, Dysbiosis","enrollment":60},{"nctId":"NCT06328088","phase":"","title":"Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis: An Open Label Pilot Study","status":"RECRUITING","sponsor":"Sir Ganga Ram Hospital","startDate":"2024-02-16","conditions":"Hepatic Encephalopathy","enrollment":40},{"nctId":"NCT02470780","phase":"PHASE2, PHASE3","title":"Treating Bacterial Overgrowth in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2015-12","conditions":"Parkinson's Disease, Small Intestinal Bacterial Overgrowth","enrollment":4},{"nctId":"NCT06234046","phase":"PHASE3","title":"Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-05-28","conditions":"Spontaneous Bacterial Peritonitis","enrollment":80},{"nctId":"NCT04910815","phase":"NA","title":"Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.","status":"UNKNOWN","sponsor":"Atmo Biosciences Pty Ltd","startDate":"2021-07-14","conditions":"Small Intestinal Bacterial Overgrowth","enrollment":150},{"nctId":"NCT06199843","phase":"NA","title":"Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-01-05","conditions":"Spontaneous Bacterial Peritonitis","enrollment":280},{"nctId":"NCT01846663","phase":"PHASE4","title":"Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2013-04-03","conditions":"Hepatic Encephalopathy","enrollment":6},{"nctId":"NCT03818672","phase":"PHASE4","title":"Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2019-01-29","conditions":"Severe Hepatic Impairment","enrollment":5},{"nctId":"NCT04592289","phase":"NA","title":"Short-term Outcomes of Full Bowel Preparation (MBP+OA) for Rectal Resections for Cancer Versus MBP Alone","status":"UNKNOWN","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2020-10-30","conditions":"Rectal Cancer","enrollment":622},{"nctId":"NCT05502913","phase":"PHASE2","title":"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer","status":"RECRUITING","sponsor":"Soroka University Medical Center","startDate":"2023-09-01","conditions":"Metastatic Lung Cancer","enrollment":80},{"nctId":"NCT06020365","phase":"NA","title":"Investigation of Fecal Microbiota Transplant in Chronic Intestinal Pseudo-obstruction Patients","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2018-01-01","conditions":"Intestinal Pseudo-Obstruction, Fecal Microbiota Transplantation","enrollment":10},{"nctId":"NCT02620007","phase":"PHASE2","title":"Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-12","conditions":"Crohn Disease, Adherent-invasive E. Coli","enrollment":24},{"nctId":"NCT05863364","phase":"NA","title":"Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis","status":"UNKNOWN","sponsor":"Xin Zeng","startDate":"2023-08-18","conditions":"Decompensated Cirrhosis","enrollment":150},{"nctId":"NCT05867550","phase":"PHASE4","title":"To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea","status":"COMPLETED","sponsor":"Bahria University","startDate":"2023-01-03","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":162},{"nctId":"NCT03780673","phase":"PHASE2, PHASE3","title":"Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2019-01-03","conditions":"Liver Cirrhoses","enrollment":254},{"nctId":"NCT04841980","phase":"PHASE4","title":"Rifaximin Therapy vs Low FODMAP Diet In IBS","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2021-04-22","conditions":"Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth","enrollment":100},{"nctId":"NCT03420144","phase":"PHASE2, PHASE3","title":"Growth Hormone Therapy in Liver Cirrhosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2018-01-15","conditions":"Cirrhosis, Liver","enrollment":76},{"nctId":"NCT03515044","phase":"PHASE2","title":"Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2018-09-13","conditions":"Overt Hepatic Encephalopathy","enrollment":71},{"nctId":"NCT05546892","phase":"NA","title":"Short-term Outcomes of Full Bowel Preparation (MBP+OA) for Colon Cancer Resections Versus no Bowel Preparation","status":"UNKNOWN","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2023-02-10","conditions":"Colon Cancer","enrollment":586},{"nctId":"NCT04557215","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Rifaximin With NAC in IBS-D","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-11-13","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":45},{"nctId":"NCT05786859","phase":"EARLY_PHASE1","title":"The Efficacy and Safety of Rifaximin Treatment","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-03-09","conditions":"Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV","enrollment":124},{"nctId":"NCT02498301","phase":"NA","title":"Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2015-11-10","conditions":"Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis","enrollment":449},{"nctId":"NCT04775329","phase":"PHASE2, PHASE3","title":"Primary Prophylaxis for Spontaneous Bacterial Peritonitis","status":"TERMINATED","sponsor":"Changi General Hospital","startDate":"2020-11-01","conditions":"Decompensated Cirrhosis, Small Bowel Bacterial Overgrowth Syndrome","enrollment":2},{"nctId":"NCT05621005","phase":"PHASE2","title":"Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients","status":"COMPLETED","sponsor":"Samar Atef Sebaweh Mohammed","startDate":"2019-03-01","conditions":"Ascites Infection","enrollment":104},{"nctId":"NCT04316806","phase":"NA","title":"Effect of a Probiotic Formula on Reducing SIBO in IBS Patients","status":"TERMINATED","sponsor":"AB Biotics, SA","startDate":"2020-11-20","conditions":"Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth","enrollment":8},{"nctId":"NCT03462966","phase":"PHASE2","title":"Rifaximin on Visceral Hypersensitivity","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-07-01","conditions":"Visceral Hypersensitivity, Irritable Bowel Syndrome","enrollment":4},{"nctId":"NCT01137955","phase":"NA","title":"Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease","status":"COMPLETED","sponsor":"Columbia University","startDate":"2006-10","conditions":"Celiac Disease","enrollment":50},{"nctId":"NCT03557788","phase":"PHASE4","title":"Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2018-05-07","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":33},{"nctId":"NCT05083572","phase":"PHASE4","title":"Effect of Probiotic on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers","status":"UNKNOWN","sponsor":"Changi General Hospital","startDate":"2021-03-10","conditions":"Dysbiosis","enrollment":32},{"nctId":"NCT02439307","phase":"NA","title":"Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial","status":"TERMINATED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2017-02-28","conditions":"Small Intestinal Bacterial Overgrowth, Liver Cirrhosis","enrollment":11},{"nctId":"NCT00748904","phase":"PHASE4","title":"Rifaximin Versus Lactulose in Renal Failure","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2008-06","conditions":"Liver Cirrhosis, Renal Failure","enrollment":""},{"nctId":"NCT02651740","phase":"PHASE2, PHASE3","title":"Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2016-04","conditions":"Irritable Bowel Syndrome","enrollment":10},{"nctId":"NCT03856359","phase":"PHASE2","title":"Trial of Rifaximin in Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-04-09","conditions":"Alzheimer's Disease","enrollment":10},{"nctId":"NCT00603616","phase":"PHASE2","title":"Induction of Clinical Response Using Rifaximin in Crohn's Disease","status":"COMPLETED","sponsor":"Scott Lee","startDate":"2008-11","conditions":"Crohn's Disease","enrollment":36},{"nctId":"NCT02342639","phase":"PHASE4","title":"Rifaximin Therapy in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Jason Stubbs, MD","startDate":"2015-06","conditions":"Chronic Kidney Disease","enrollment":38},{"nctId":"NCT02555293","phase":"PHASE2","title":"Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2016-02","conditions":"Malignant Liver Disease, Major Liver Resection","enrollment":96},{"nctId":"NCT03469050","phase":"PHASE2, PHASE3","title":"Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.","status":"TERMINATED","sponsor":"Alfasigma S.p.A.","startDate":"2018-07-02","conditions":"Diverticulitis","enrollment":193},{"nctId":"NCT01670149","phase":"PHASE4","title":"Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2012-12","conditions":"Clostridium Difficile Infection","enrollment":151},{"nctId":"NCT03529825","phase":"EARLY_PHASE1","title":"Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-07-18","conditions":"Microbial Colonization","enrollment":26},{"nctId":"NCT02272868","phase":"PHASE1, PHASE2","title":"Fecal Microbial Transplant in Pediatric Crohn's Disease","status":"TERMINATED","sponsor":"Seattle Children's Hospital","startDate":"2015-01","conditions":"Crohn's Disease","enrollment":7},{"nctId":"NCT03537157","phase":"PHASE2","title":"A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention","status":"TERMINATED","sponsor":"Alfasigma S.p.A.","startDate":"2017-11-16","conditions":"Crohn Disease","enrollment":43},{"nctId":"NCT04128462","phase":"PHASE3","title":"MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function","status":"WITHDRAWN","sponsor":"Mallinckrodt","startDate":"2021-11","conditions":"Hepatic Encephalopathy","enrollment":""},{"nctId":"NCT04003181","phase":"NA","title":"The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2017-09-28","conditions":"Colon Adenocarcinoma, Diarrhea","enrollment":64},{"nctId":"NCT03613545","phase":"PHASE2, PHASE3","title":"Fecal Microbiota Transplantation for Irritable Bowel Syndrome","status":"RECRUITING","sponsor":"Guangzhou First People's Hospital","startDate":"2018-08-10","conditions":"Irritable Bowel Syndrome, Fecal Microbiota Transplantation","enrollment":120},{"nctId":"NCT03712280","phase":"PHASE2","title":"MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2018-12-01","conditions":"Hepatic Cirrhosis, Hepatic Encephalopathy (HE)","enrollment":50},{"nctId":"NCT03077217","phase":"PHASE4","title":"Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Shanghai Changzheng Hospital","startDate":"2017-05-01","conditions":"Covert Hepatic Encephalopathy","enrollment":40},{"nctId":"NCT04118699","phase":"PHASE2","title":"Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial","status":"UNKNOWN","sponsor":"Yokohama City University","startDate":"2019-12-25","conditions":"Chronic Intestinal Pseudo-obstruction","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"VOMITING"},{"count":2,"reaction":"ABDOMINAL PAIN"},{"count":2,"reaction":"CHILLS"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PYREXIA"},{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"ANIMAL BITE"},{"count":1,"reaction":"BLISTER"},{"count":1,"reaction":"BOWEL MOVEMENT IRREGULARITY"},{"count":1,"reaction":"CARDIAC ARREST"}],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["XIFAXAN","Xifaxan®"],"phase":"marketed","status":"active","brandName":"Rifaximin (XIFAXAN)","genericName":"Rifaximin (XIFAXAN)","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifaximin is a non-absorbed antibiotic that inhibits bacterial RNA polymerase to reduce pathogenic gut bacteria without systemic absorption. Used for Traveler's diarrhea caused by noninvasive strains of Escherichia coli, Hepatic encephalopathy (reduction of overt episodes), Irritable bowel syndrome with diarrhea (IBS-D).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}